おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Oyster Point Pharmaceuticals
About
Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $93M
- Industries
- Biopharma,Clinical Trials,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 26, 2019 | Series B | $93M | 1 | — | — | Detail |
| Nov 7, 2017 | Series A | $22M | 1 |
Versant Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
— | Series B |
